These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 17889401

  • 1. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
    Lee HW, Han JH, Kim JH, Lee MH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, Hwang SC, Sheen SS, Lim HY.
    Lung Cancer; 2008 Jan; 59(1):95-104. PubMed ID: 17889401
    [Abstract] [Full Text] [Related]

  • 2. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
    Jeong SH, Jung JH, Han JH, Kim JH, Choi YW, Lee HW, Kang SY, Hwang YH, Ahn MS, Choi JH, Oh YT, Chun M, Kang S, Park KJ, Hwang SC, Sheen SS.
    Lung Cancer; 2010 May; 68(2):288-94. PubMed ID: 19560836
    [Abstract] [Full Text] [Related]

  • 3. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P.
    Clin Cancer Res; 2007 Jul 01; 13(13):3855-9. PubMed ID: 17606717
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
    Sohn SK, Jung JT, Kim DH, Kim JG, Kwak EK, Park Ti, Shin DG, Sohn KR, Lee KB.
    Am J Hematol; 2003 Jun 01; 73(2):101-7. PubMed ID: 12749011
    [Abstract] [Full Text] [Related]

  • 5. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy.
    Kang SY, Han JH, Lee KJ, Choi JH, Park JI, Kim HI, Lee HW, Jang JH, Park JS, Kim HC, Kang S, Oh YT, Chun M, Kim JH, Sheen SS, Lim HY.
    Clin Cancer Res; 2007 Jul 15; 13(14):4146-53. PubMed ID: 17634542
    [Abstract] [Full Text] [Related]

  • 6. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC.
    Clin Cancer Res; 2004 Aug 01; 10(15):4939-43. PubMed ID: 15297394
    [Abstract] [Full Text] [Related]

  • 7. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E, Knez L, Kern I, Ovčariček T, Sadikov A, Cufer T.
    Eur J Cancer; 2012 Dec 01; 48(18):3378-85. PubMed ID: 22795264
    [Abstract] [Full Text] [Related]

  • 8. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
    Giatromanolaki A, Sivridis E, Stathopoulos GP, Fountzilas G, Kalofonos HP, Tsamandas A, Vrettou E, Scopa C, Polychronidis A, Simopoulos K, Koukourakis MI.
    Anticancer Res; 2001 Dec 01; 21(1A):253-9. PubMed ID: 11299743
    [Abstract] [Full Text] [Related]

  • 9. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun 01; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 10. Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma.
    Santini D, Tonini G, Vecchio FM, Borzomati D, Vincenzi B, Valeri S, Antinori A, Castri F, Coppola R, Magistrelli P, Nuzzo G, Picciocchi A.
    J Clin Pathol; 2005 Feb 01; 58(2):159-65. PubMed ID: 15677536
    [Abstract] [Full Text] [Related]

  • 11. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
    Yakirevich E, Sabo E, Naroditsky I, Sova Y, Lavie O, Resnick MB.
    Gynecol Oncol; 2006 Jan 01; 100(1):152-9. PubMed ID: 16198399
    [Abstract] [Full Text] [Related]

  • 12. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy.
    Wootipoom V, Lekhyananda N, Phungrassami T, Boonyaphiphat P, Thongsuksai P.
    Gynecol Oncol; 2004 Sep 01; 94(3):636-42. PubMed ID: 15350352
    [Abstract] [Full Text] [Related]

  • 13. Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer.
    Porebska I, Wyrodek E, Kosacka M, Adamiak J, Jankowska R, Harłozińska-Szmyrka A.
    In Vivo; 2006 Sep 01; 20(5):599-604. PubMed ID: 17091766
    [Abstract] [Full Text] [Related]

  • 14. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
    Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, Hahner S, Allolio B, Fassnacht M.
    Endocr Relat Cancer; 2009 Sep 01; 16(3):907-18. PubMed ID: 19240185
    [Abstract] [Full Text] [Related]

  • 15. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R.
    J Clin Oncol; 2007 Jul 01; 25(19):2747-54. PubMed ID: 17602080
    [Abstract] [Full Text] [Related]

  • 16. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
    Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y.
    Lung Cancer; 2008 Oct 01; 62(1):105-12. PubMed ID: 18395930
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma.
    Allal AS, Waelchli L, Bründler MA.
    Clin Cancer Res; 2003 Dec 15; 9(17):6489-96. PubMed ID: 14695153
    [Abstract] [Full Text] [Related]

  • 18. [ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma].
    Sobajima J, Haga N, Kumamoto K, Ishibashi K, Ishida H.
    Gan To Kagaku Ryoho; 2010 Nov 15; 37(12):2394-6. PubMed ID: 21224584
    [Abstract] [Full Text] [Related]

  • 19. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
    Pollack A, Cowen D, Troncoso P, Zagars GK, von Eschenbach AC, Meistrich ML, McDonnell T.
    Cancer; 2003 Apr 01; 97(7):1630-8. PubMed ID: 12655519
    [Abstract] [Full Text] [Related]

  • 20. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.
    Lee HW, Choi YW, Han JH, Kim JH, Jung JH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, Hwang SC, Sheen SS.
    Lung Cancer; 2009 Sep 01; 65(3):377-82. PubMed ID: 19150580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.